» Articles » PMID: 38067602

Resistomycin Suppresses Prostate Cancer Cell Growth by Instigating Oxidative Stress, Mitochondrial Apoptosis, and Cell Cycle Arrest

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Dec 9
PMID 38067602
Authors
Affiliations
Soon will be listed here.
Abstract

Globally, prostate cancer is among the most threatening and leading causes of death in men. This study, therefore, aimed to search for an ideal antitumor strategy with high efficacy, low drug resistance, and no or few adverse effects. Resistomycin is a natural antibiotic derived from marine actinomycetes, and it possesses various biological activities. Prostate cancer cells (PC3) were treated with resistomycin (IC.: 0.65 or IC: 1.3 µg/mL) or 5-fluorouracil (5-FU; IC: 7 µg/mL) for 24 h. MTT assay and flow cytometry were utilized to assess cell viability and apoptosis. Oxidative stress, apoptotic-related markers, and cell cycle were also assessed. The results revealed that the IC of resistomycin and 5-FU on PC3 cells were 2.63 µg/mL and 14.44 µg/mL, respectively. Furthermore, treated cells with the high dose of resistomycin showed an increased number of apoptotic cells compared to those treated with the lower dose. Remarkable induction of reactive oxygen species generation and lactate dehydrogenase (LDH) leakage with high malondialdehyde (MDA), carbonyl protein (CP), and 8-hydroxyguanosine (8-OHdG) contents were observed in resistomycin-treated cells. In addition, marked declines in glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) in PC3 cells subjected to resistomycin therapy were observed. Resistomycin triggered observable cell apoptosis by increasing Bax, caspase-3, and cytosolic cytochrome c levels and decreasing Bcl-2 levels. In addition, notable downregulation of proliferating cell nuclear antigen (PCNA) and cyclin D1 was observed in resistomycin-treated cancerous cells. According to this evaluation, the antitumor potential of resistomycin, in a concentration-dependent manner, in prostate cancer cells was achieved by triggering oxidative stress, mitochondrial apoptosis, and cell cycle arrest in cancer cells. In conclusion, our investigation suggests that resistomycin can be considered a starting point for developing new chemotherapeutic agents for human prostate cancer.

Citing Articles

In Silico Analysis of Non-Conventional Oxidative Stress-Related Enzymes and Their Potential Relationship with Carcinogenesis.

Seiva F, Agneis M, de Almeida M, Caputo W, de Souza M, das Neves K Antioxidants (Basel). 2024; 13(11).

PMID: 39594421 PMC: 11591236. DOI: 10.3390/antiox13111279.


RBM15B Promotes Prostate Cancer Cell Proliferation via PCNA m6A Modification.

Cheng H, Chen Z, Wang Y, Ji C, Wang J, Song N Cell Biochem Biophys. 2024; 83(1):1237-1248.

PMID: 39361104 DOI: 10.1007/s12013-024-01558-5.


The Potential Anticancer Potency of Kolaviron on Colorectal Adenocarcinoma (Caco-2) Cells.

Althagafi H Anticancer Agents Med Chem. 2024; 24(15):1097-1108.

PMID: 38835121 DOI: 10.2174/0118715206288807240527165444.

References
1.
Cao H, Feng Y, Chen L, Yu C . Lobaplatin Inhibits Prostate Cancer Proliferation and Migration Through Regulation of BCL2 and BAX. Dose Response. 2019; 17(2):1559325819850981. PMC: 6557032. DOI: 10.1177/1559325819850981. View

2.
Zhu M, Zheng Z, Huang J, Ma X, Huang C, Wu R . Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells. J Cell Biochem. 2019; 120(9):15616-15624. DOI: 10.1002/jcb.28828. View

3.
Nazari M, Machado B, Marchezi G, Crestani L, Ferrari V, Colla L . Use of soil actinomycetes for pharmaceutical, food, agricultural, and environmental purposes. 3 Biotech. 2022; 12(9):232. PMC: 9391553. DOI: 10.1007/s13205-022-03307-y. View

4.
Lin M, Islam A, Liu Y, Weng C, Zhan J, Liang R . Antibiotic heliomycin and its water-soluble 4-aminomethylated derivative provoke cell death in T24 bladder cancer cells by targeting sirtuin 1 (SIRT1). Am J Cancer Res. 2022; 12(3):1042-1055. PMC: 8984893. View

5.
AEBI H . Catalase in vitro. Methods Enzymol. 1984; 105:121-6. DOI: 10.1016/s0076-6879(84)05016-3. View